Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.70 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.66 |
| ▸ | MAOB | P27338 | 4/20 | 0.65 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.65 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.65 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.65 |
| ▸ | AR | P10275 | 2/20 | 0.64 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.63 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | PKM | P14618 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4864045 | 0.93 | NFE2L2 (0.72) | NFE2L2ABCG2MAOBALOX5CYP1A1 | |
| SCHEMBL5084423 | 0.90 | MAOB (0.80) | NFE2L2ABCG2MAOBALOX5CYP1A1 | |
| SCHEMBL5084427 | 0.90 | MAOB (0.80) | NFE2L2ABCG2MAOBALOX5CYP1A1 | |
| SCHEMBL7096835 | 0.89 | NFE2L2 (0.63) | NFE2L2MAOBALOX5CYP1A1CYP1A2 | |
| SCHEMBL11073098 | 0.88 | NFE2L2 (0.59) | NFE2L2ABCG2MAOBALOX5CYP1A1 | |
| SCHEMBL4535102 | 0.88 | AR (0.80) | NFE2L2ABCG2MAOBCYP1A1CYP1A2 | |
| SCHEMBL7097185 | 0.87 | ALDH1A1 (0.68) | NFE2L2MAOBALOX5CYP1A1CYP1A2 | |
| SCHEMBL7099531 | 0.87 | PTPN1 (0.61) | NFE2L2MAOBALOX5CYP1A1CYP1A2 | |
| SCHEMBL27794060 | 0.87 | NFE2L2 (0.60) | NFE2L2ABCG2MAOBALOX5CYP1A1 | |
| SCHEMBL4026900 | 0.85 | LMNA (0.78) | NFE2L2ABCG2MAOBALOX5CYP1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115624544-B | Application of chalcone analogue as active substance in preparation of antitumor drugs | 甘肃中医药大学 | 2025-01-24 | — | — | CN | claimed |
| EP-0021000-B1 | SUBSTITUTED ACETOPHENONES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1984-02-22 | — | — | EP | claimed |
| EP-4598515-A1 | PHYTOCHEMICAL FORMULATIONS FOR TREATING STRESS AND ANXIETY | GBS Global Biopharma, Inc. (CA) | 2025-08-13 | — | — | EP | disclosed |
| EP-4429763-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | Yewsavin, Inc. (US) | 2024-09-18 | — | — | EP | disclosed |
| EP-2984072-B1 | SYNTHETIC ANALOGUES OF XANTHOHUMOL | UNIV PISA (IT) | 2024-05-29 | — | — | EP | disclosed |
| WO-2024054462-A1 | PHYTOCHEMICAL FORMULATIONS FOR TREATING STRESS AND ANXIETY | GBS GLOBAL BIOPHARMA, INC. (CA) | 2024-03-14 | — | — | WO | disclosed |
| WO-2023086388-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2023-05-19 | — | — | WO | disclosed |
| CN-115624544-A | Application of chalcone analogue as active substance in preparation of antitumor drugs | 甘肃中医药大学 | 2023-01-20 | — | — | CN | disclosed |
| US-9617213-B2 | Synthetic analogues of xanthohumol | UNIVERSITA' DI PISA (IT) | 2017-04-11 | — | — | US | disclosed |
| US-20160075652-A1 | SYNTHETIC ANALOGUES OF XANTHOHUMOL | AZIENDA OSPEDALIERA DI REGGIO EMILIA ARCISPEDALE S. MARIA NUOVA IRCCS (IT) | 2016-03-17 | — | — | US | disclosed |
| US-20110124721-A1 | METHODS OF TREATING TRAUMATIC BRAIN INJURY BY ADMINISTERING BAICALEIN PREPARATION | NATIONAL DEFENSE MEDICAL CENTER (TW) | 2011-05-26 | — | — | US | disclosed |
| US-20100222421-A1 | Usage of Baicalein in the Preparation of a Pharmaceutical Composition for the Treatment of Traumatic Brain Injury | NATIONAL DEFENSE MEDICAL CENTER (TW) | 2010-09-02 | — | — | US | disclosed |
| US-20080287374-A1 | BREAST CANCER-RESISTANT PROTEIN INHIBITOR | KABUSHIKI KAISHA YAKULT HONSHA (JP) | 2008-11-20 | — | — | US | disclosed |
| EP-1888174-A1 | USE OF CHALCONES FOR THE TREATMENT OF VIRAL DISORDERS | Johnson and Johnson Consumer Companies, Inc. (US) | 2008-02-20 | — | — | EP | disclosed |
| US-7326734-B2 | Treatment of bladder and urinary tract cancers | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-02-05 | — | — | US | disclosed |
| WO-2006127539-A1 | USE OF CHALCONES FOR THE TREATMENT OF VIRAL DISORDERS | JOHNSON & JOHNSON CONSUMER COMPANIES, INC. (US) | 2006-11-30 | — | — | WO | disclosed |
| US-20060135445-A1 | Breast cancer-resistant protein inhibitor | KABUSHIKI KAISHA YAKULT HONSHA (JP) | 2006-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160075652-A1 | SYNTHETIC ANALOGUES OF XANTHOHUMOL | XDH, XPA, NR1H3 | NFE2L2 3341/4885ABCG2 1193/4885MAOB 1648/4885 |
| US-20060135445-A1 | Breast cancer-resistant protein inhibitor | ABCC1, BCR, BRCA1 | NFE2L2 1167/4885ABCG2 8/4885MAOB 3350/4885 |
| US-20080287374-A1 | BREAST CANCER-RESISTANT PROTEIN INHIBITOR | ABCC1, BCR, BRCA1 | NFE2L2 1167/4885ABCG2 8/4885MAOB 3350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.